Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting
New evidence from the world’s first genome-wide association study (GWAS) identifies genes and genetic variants associated with bedwetting and may lead to earlier identification of children predisposed to bedwetting and improved earlier treatment options.The results are being presented by the International Children’s Continence Society (ICCS) and the European Society for Paediatric Urology (ESPU) on World Bedwetting Day on 29 May 2018.
“We have known for over a century, there has been strong evidence suggesting a genetic background for bedwetting.2 The risk of bedwetting is 5-7 times higher among children with a parent who suffered from bedwetting as a child, and approximately 11 times higher if both parents were bedwetters”,1 said Dr. Søren Rittig, Professor at the Department of Child and Youth, Nephro-urologic Team, Aarhus University Hospital who together with associate professor Jane Hvarregaard Christensen, Department of Biomedicine, Aarhus University is responsible for this new study.
Bedwetting is a common medical condition that has a serious impact on a child’s self-esteem, emotional well-being and day time functioning, including school and social performance3,4,5; and improvements in their working memory and other daily activities have been seen after treatment.6
The GWAS used the iPSYCH2012 nationwide population-based sample of around 80,000 Danish individuals collected to study among others ADHD and autism. Genome-wide association studies work by scanning markers across the entire genome of large numbers of people in order to find genetic variants associated with a particular disease.
Associate professor Jane Hvarregaard Christensen said, “By comparing the frequency of millions of genetic variants in thousands of DNA samples from bedwetting children we have been able to demonstrate specific genetic variants that each contribute to increase the risk of bedwetting. The genes implicated by this are known to function in deep brain areas responsible for regulation of day-night rhythms, urine production and sleep. This supports that bedwetting is linked to physiological mechanisms rather than being caused by psychological problems.” This is an important first step to provide new insights into the biological processes leading to bedwetting.
There are at least two main reasons why children are bedwetting – a reduced bladder capacity and/or an increased urine production during night-time (polyuria). By analyzing millions of genetic variants in bedwetting children, researchers were able to point to specific genes and thereby suggest specific biological causes of bedwetting.
Dr. Søren Rittig said, “We believe further research using the genes and genetic variants we have detected could help us identify bedwetting children earlier, determine which children would benefit from medication and tailor treatment to alleviate their condition.”
Bedwetting, also known as nocturnal enuresis, is an uncontrollable leakage of urine while asleep.7 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.4 An inability to wake up can be another cause.4 Bedwetting does not seem to have a psychological cause.4 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.8
About World Bedwetting Day
World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated.
World Bedwetting Day 2018 will take place on 29 May and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.
For more information please visit www.worldbedwettingday.com.
About the World Bedwetting Day Steering Committee
The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), and the North American Paediatric Urology Societies. The initiative is supported by Ferring Pharmaceuticals.
1 Jarvelin, M. R., Vikevainen-Tervonen, L., Moilanen, I. &
Huttunen, N. P. Enuresis in seven-year-old children. Acta paediatrica
77, 148-153 (1988).
2 von Gontard, A., Schaumburg, H., Hollmann, E., Eiberg, H. & Rittig, S. The genetics of enuresis: a review. The Journal of urology 166, 2438-2443 (2001).
3 Iannelli V. Bedwetting. Available at https://www.verywell.com/bedwetting-bedwetting-statistics-2633257. Last accessed January 2017.
4 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-98
5 Joinson C et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting Pediatrics. 2007;120(2):e308-16
6 Van Herzeele C, Dhondt K, Roels S P et al. Desmopressin (melt) therapy in children with monosymptomatic nocturnal enuresis and nocturnal polyuria results in improved neuropsychological functioning and sleep. Pediatr Nephrol. 2016; DOI 10.1007/s00467-016-23351-3
7 Austin P et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report from the Standardization Committee of the International Children’s Continence Society, The Journal of Urology. 2014;191:1863-1865
8 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214
Burson-Marsteller, on behalf of World Bedwetting Day Steering Committee
Jack Dixey, +44 (0)207 300 6221
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third